文献速递免疫规划

非嗜神经性1型单纯疱疹病毒减毒活疫苗VC-2的交叉保护效力可通过皮内接种和糖蛋白G缺失而增强

Cross protective efficacy of the Non-Neurotropic live attenuated herpes simplex virus type 1 vaccine VC-2 is enhanced by intradermal vaccination and deletion of glycoprotein G.
PubMed 文献 · Vaccine · 2022-09-14

在豚鼠模型中评估非嗜神经性1型单纯疱疹病毒减毒活疫苗VC-2皮内接种及糖蛋白G缺失对预防生殖道2型单纯疱疹病毒病的效力。VC-2、VC-2 gG缺失株或gD2 MPL/Alum佐剂疫苗均能强效预防急性病,但VC-2 gG缺失株皮内接种在减少阴道复制和复发性排毒方面优于肌内接种的母本VC-2;仅VC-2皮内接种显著降低背根神经节病毒载量。作者认为需进一步研究皮内接种的VC-2 gG缺失株。

要点

  • VC-2、VC-2 gG缺失株或gD2 MPL/Alum佐剂疫苗均能强效预防急性病,与接种途径无关。
  • VC-2 gG缺失株皮内接种比肌内接种的母本VC-2更有效减少第2天和第4天阴道复制及复发性病变评分。
  • 仅VC-2 gG缺失株肌内接种和VC-2皮内接种显著降低复发性排毒频率。

核心结论

  • VC-2 gG缺失株皮内接种比肌内接种的母本VC-2更有效减少HSV-2阴道复制和复发性病变评分,且仅VC-2 gG缺失株肌内接种和VC-2皮内接种显著降低复发性排毒频率。
  • 仅VC-2皮内接种显著降低背根神经节病毒载量。
  • 所有疫苗接种组均诱导了针对HSV-2 MS的中和抗体。
  • 作者认为需进一步研究皮内接种的VC-2 gG缺失株。

研究设计与样本

  • 在豚鼠模型中研究皮内接种及病毒糖蛋白G缺失对预防性疫苗接种效力的影响。
  • 比较VC-2、VC-2 gG缺失株或gD2 MPL/Alum佐剂疫苗不同接种途径的效力。

主要发现

  • VC-2、VC-2 gG缺失株或gD2 MPL/Alum佐剂疫苗均能强效预防急性病,与接种途径无关。
  • VC-2 gG缺失株皮内接种比肌内接种的母本VC-2更有效减少第2天和第4天HSV-2阴道复制及复发性病变评分。
  • 仅VC-2 gG缺失株肌内接种和VC-2皮内接种显著降低复发性排毒频率。
  • 所有疫苗接种组均显著减少攻击后背根神经节HSV-2 PCR阳性动物数,但仅VC-2皮内接种组显著降低背根神经节病毒载量。
  • 所有疫苗接种组均诱导了针对HSV-2 MS的中和抗体。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Herpes simplex virus type 1 and 2 (HSV-1 and HSV-2 respectively) cause life-long latent infections resulting in recurrent orofacial and genital blisters or sores. Ensued disease can be painful and may lead to significant mental anguish of infected individuals. Currently, there are no FDA-approved vaccines for either prophylactic or therapeutic use, and recent clinical trials of subunit vaccines failed to achieve endpoints goals. Development of a safe live-attenuated herpes simplex vaccine may provide the antigenic breadth to ultimately protect individuals from acquiring HSV disease. We have previously shown that prophylactic use of the non-neurotropic live attenuated HSV-1 vaccine, VC-2, provides potent and durable protection from genital HSV-2 disease in the guinea pig model. Here, we investigated the effects of intradermal administration as well as the deletion of the viral glycoprotein G (gG) on the efficacy of prophylactic vaccination. Vaccination with either VC-2, VC-2 gG null, or gD2 MPL/Alum offered robust protection from acute disease regardless of route of vaccination. However, both the VC-2 gG-null and the ID vaccination route were more effective compared to the parent VC2 administered by the IM route. Specifically, the VC-2 gG-null administered ID, reduced HSV-2 vaginal replication on day 2 and day 4 as well as mean recurrent lesion scores more effectively than VC2 administered IM. Most importantly, only VC-2 gG null IM and VC-2 ID significantly reduced the frequency of recurrent shedding, the most likely source for virus transmission. Similarly, while all vaccinated groups demonstrated a significant reduction in the number of animals testing PCR-positive for HSV-2 in their dorsal root ganglia following challenge only VC2 ID vaccinated animals demonstrated a significant reduction in DRG viral load. All vaccinations induced neutralizing antibodies to HSV-2 MS when compared to unvaccinated guinea pigs. Therefore, further investigation of VC-2 gG null delivered ID is warranted.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Stanfield BA, Bravo FJ, Dixon DA, et al. Cross protective efficacy of the Non-Neurotropic live attenuated herpes simplex virus type 1 vaccine VC-2 is enhanced by intradermal vaccination and deletion of glycoprotein G. Vaccine. 2022. PMID: 36114130. doi:10.1016/j.vaccine.2022.09.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。